PAS-004

PAS-004 is a small molecule (oral, macrocyclic) from Pasithea Therapeutics. An oral small-molecule allosteric inhibitor of MEK1 and MEK2 with a macrocyclic structure designed to improve metabolic stability and its pharmacokinetic profile. Its furthest stage is phase 1, for MAPK pathway-driven advanced solid tumours (RAS, NF1 or RAF mutations) and NF1-associated plexiform neurofibromas. ClinicalTrials.gov registers it in 2 studies linked below. Two phase 1 trials recruiting: NCT06299839 (advanced solid tumours with RAS, NF1 or RAF mutations) and NCT06961565 (adults with NF1 plexiform neurofibromas). Whether it works in people has not been established unless a trial below reports it.